经颅直流电刺激治疗缺血性脑卒中后中枢性疼痛的效果

Efficacy of transcranial direct current stimulation in treating central pain after ischemic stroke

目的探讨经颅直流电刺激(tDCS)辅助普瑞巴林治疗缺血性脑卒中后中枢性疼痛的效果,以期为临床治疗提供参考。方法选取2021年1月—2024年1月宝鸡市人民医院诊治的102例缺血性脑卒中后中枢性疼痛患者为研究对象,采用随机数字表法将患者分为对照组与观察组,每组51例。2组患者均进行常规药物治疗,给予患者普瑞巴林治疗,观察组患者在此基础上使用爱君仪tDCS治疗。比较2组患者治疗前后的视觉模拟评分法(VAS)评分、匹茨堡睡眠质量指数量表(PSQI)评分、疼痛缓解度(PAR);比较2组患者治疗后发生的不良反应情况。结果治疗前,2组患者VAS及PSQI评分比较,差异均无统计学意义(P>0.05)。治疗后,2组患者VAS及PSQI评分均低于治疗前,且观察组低于对照组,差异均有统计学意义(P<0.05)。观察组患者疼痛缓解总有效率(96.08%)高于对照组(82.35%),差异有统计学意义(P<0.05)。2组患者不良反应总发生率比较,差异无统计学意义(P>0.05)。结论使用tDCS辅助普瑞巴林治疗缺血性脑卒中后中枢性疼痛患者,能够较好地缓解患者的疼痛症状,且具有较高的安全性,有一定的临床应用价值。

Objective To explore the clinical efficacy of transcranial direct current stimulation(tDCS)combined with pregabalin in the treatment of patients with central pain after ischemic stroke,with the aim of providing a reference for clinical treatment.Methods A total of 102 patients with central pain after ischemic stroke treated at Baoji People's Hospital from January 2021 to January 2024 were selected as the study participants.Patients were assigned to a control group(n=51)and an observation group(n=51)using the random number table method.Both groups of patients received conventional drug treatment with pregabalin,and the observation group additionally received tDCS treatment using the Aijunyi tDCS therapy device.The Visual Analog Scale(VAS)scores,Pittsburgh Sleep Quality Index(PSQI),and pain relief(PAR)scores before and after treatment in the two groups of patients were compared.The incidence of adverse reactions after treatment in the two groups of patients was also compared.Results Before treatment,no significant difference was noted in VAS and PSQI scores between the two groups(P>0.05).Both groups had significantly lower VAS and PSQI scores after treatment,with the observation group having significantly lower scores than the control group(P<0.05).The overall response rate of pain relief in the observation group was significantly higher than that in the control group(96.08%vs.82.35%;P<0.05).No statistically significant difference was found in the overall incidence of adverse reactions between the two groups(P>0.05).Conclusion The use of tDCS combined with pregabalin in treating patients with central pain after ischemic stroke can effectively alleviate patients'pain symptoms and has a high safety profile,making it valuable for clinical application.